<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752256</url>
  </required_header>
  <id_info>
    <org_study_id>IRB:201507803</org_study_id>
    <nct_id>NCT02752256</nct_id>
  </id_info>
  <brief_title>Thrombolytic Care During Inter-hospital Transfer</brief_title>
  <official_title>Quality and Effectiveness of Thrombolytic Care During Inter-hospital Transfer (&quot;Drip-Ship&quot;) With Air Ambulance Services</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of ischemic stroke patients receiving tissue plasminogen activator (rtPA) during
      air ambulance transfer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of our study is to evaluate the effect of air ambulance transport on patients
      presenting with an ischemic stroke and receive tissue plasminogen activator (rtPA). Primary
      outcome will be the evaluation of air ambulance transfer and if it leads to protocol
      violations or significant delays in therapy. Protocol violations include inaccurate dosing or
      preparation at the outside hospital, uncontrolled blood pressure before and during the
      flight, unnecessary medication administration before and during the flight and adverse events
      (intracranial bleeding, allergic reaction) associated with transfer process. Additional
      evaluation will include the effects of vibration of the air ambulance and its effects on the
      lytic activity of rtPA. rtPA is not supposed to be significantly agitated after it is
      prepared in solution and there is significant vibration and agitation during air ambulance
      transfer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a rtPA Protocol Violation</measure>
    <time_frame>24 hours</time_frame>
    <description>Protocol violations can include any of the following recorded outcomes: inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight, intracranial bleeding, and angioedema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Time to rtPA</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">76</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention/Transfer</arm_group_label>
    <description>Patients who are transferred via air ambulance to a comprehensive stroke center</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients presenting directly to the comprehensive stroke center</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention/Transfer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All acute ischemic stroke patients who receive rtPA and transferred to our institution via
        our air ambulance service or present directly to our ED
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received tissue plasminogen activator for acute ischemic stroke

          -  presented directly to comprehensive stroke center or were transferred by our air
             ambulance service

        Exclusion Criteria:

          -  Transferred by another air ambulance service or ground ambulance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>June 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Brett A Faine</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist</investigator_title>
  </responsible_party>
  <keyword>tissue plasminogen activator</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02752256/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention/Transfer</title>
          <description>Patients who are transferred via air ambulance to a comprehensive stroke center
Tissue Plasminogen Activator</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Patients presenting directly to the comprehensive stroke center
Tissue Plasminogen Activator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention/Transfer</title>
          <description>Patients who are transferred via air ambulance to a comprehensive stroke center
Tissue Plasminogen Activator</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Patients presenting directly to the comprehensive stroke center
Tissue Plasminogen Activator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="14.3"/>
                    <measurement group_id="B2" value="65" spread="22.2"/>
                    <measurement group_id="B3" value="66" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NIH Stroke Scale/Score (NIHSS)</title>
          <description>Minimum 0 (good clinical outcome), Maximum 42 (poor clinical outcome)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="8"/>
                    <measurement group_id="B2" value="6" spread="5"/>
                    <measurement group_id="B3" value="7" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a rtPA Protocol Violation</title>
        <description>Protocol violations can include any of the following recorded outcomes: inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight, intracranial bleeding, and angioedema</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention/Transfer</title>
            <description>Patients who are transferred via air ambulance to a comprehensive stroke center
Tissue Plasminogen Activator</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Patients presenting directly to the comprehensive stroke center
Tissue Plasminogen Activator</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a rtPA Protocol Violation</title>
          <description>Protocol violations can include any of the following recorded outcomes: inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight, intracranial bleeding, and angioedema</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Time to rtPA</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention/Transfer</title>
            <description>Patients who are transferred via air ambulance to a comprehensive stroke center
Tissue Plasminogen Activator</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Patients presenting directly to the comprehensive stroke center
Tissue Plasminogen Activator</description>
          </group>
        </group_list>
        <measure>
          <title>Average Time to rtPA</title>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="34.2"/>
                    <measurement group_id="O2" value="60" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In-hospital mortality, serious adverse events, adverse events up to 90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention/Transfer</title>
          <description>Patients who are transferred via air ambulance to a comprehensive stroke center
Tissue Plasminogen Activator</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Patients presenting directly to the comprehensive stroke center
Tissue Plasminogen Activator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brett Faine</name_or_title>
      <organization>University of Iowa Hospitals and Clinics</organization>
      <phone>319-384-6800</phone>
      <email>brett-faine@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

